Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies.
The pharmacokinetics of benoxaprofen in therapeutic doses of 400 or 600 mg as a solution, capsule or tablet were determined in 44 men after single or multiple doses. The plasma levels of the drug after oral administration of a solution best fitted a 2-compartment open pharmacokinetic model, whereas the levels after the solid dosage forms more appropriately fitted the simple 1-compartment open model. The plasma elimination half-life of the drug, when in solid dosage form, was found to be in the range of 19-26 h, justifying once-a-day dosage. Steady state levels of benoxaprofen were obtained after the 5th dose of a 400 mg capsule every 24 h.
D000284:Administration, Oral; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D001241:Aspirin / Q000494:pharmacology; D001583:Benzoxazoles / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D002214:Capsules; D004347:Drug Interactions; D006801:Humans; D007408:Intestinal Absorption; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010316:Particle Size; D011422:Propionates / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D012996:Solutions; D013237:Stereoisomerism; D013607:Tablets
D000893:Anti-Inflammatory Agents; D001583:Benzoxazoles; D002214:Capsules; D011422:Propionates; D012996:Solutions; D013607:Tablets; C011677:benoxaprofen; D001241:Aspirin